Introduction

The National Neisseria Network (NNN), Australia comprises reference laboratories in each State and Territory that report data on sensitivity to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP)
.
Results
A summary of the proportion of isolates with decreased susceptibility to ceftriaxone, and the proportion resistant to azithromycin, penicillin, and ciprofloxacin for Quarter 1 2018 are shown in Table 1 . 
Ceftriaxone
In the first quarter of 2018 the proportion of isolates with ceftriaxone DS in Australia was 1.7%, slightly higher than the proportion in the first quarter of 2017, and the annual proportion for 2017. Of note there two isolates reported in Australia that had high MIC values to ceftriaxone, (0.25mg/L and 0.50mg/L) that also had high level resistance to azithromycin (MIC >256mg/L), and were resistant to penicillin and ciprofloxacin, but susceptible to spectinomycin and gentamicin. Genetic analyses showed these two strains were indistinguishable. 1 Both strains were isolated from persons residing in Queensland. This was the first time NG strains with an extensively drug resistant profile have been reported in Australia, and a strain with a similar profile has also been reported in the United Kingdom. 2 The category of ceftriaxone DS as reported by the AGSP includes the MIC values 0.06 and ≥0.125 mg/L, and the national trend since 2010 is shown in Table 2 . 
Azithromycin
In the first quarter of 2018, the proportion of isolates with resistance to azithromycin in Australia was 6.0%, lower than the proportion reported nationally for 2017 (9.3%), but three times the level reported in Australia for 2013-2015 (2.1%-2.6%). 3 Initially, in 2016 the highest incidence of azithromycin resistance was reported from South Australia (19.5% in 2016, compared with 2.8% in 2015), where an outbreak of strains with low level azithromycin was reported in 2016 with a subsequent change in treatment guidelines. 4 Globally there have been increasing reports of azithromycin resistance in N. gonorrhoeae. 5 In quarter 1 2018 most states reported isolates with resistance to azithromycin, with the exception of Tasmania, remote Northern Territory and remote Western Australia. The states that reported an increase in the proportion of NG isolates with resistance to azithromycin when compared with the annual data for 2017 were Queensland, the Australian Capital Territory and urban Northern Territory, while the other states reported a decrease from 2017 annually.
The national trend of azithromycin resistance in isolates since 2012 is shown in Table 4 . 
